Appendix

Appendix Table 1: Interview Participants, by Stakeholder Type

Respondent Role	Round 1 (4-6 months)*	Round 2 (12 months)±	Total
Total Identified	50	40	90
Total Participating			
Implementation Intervention Plan Domain leads (i.e. Infection Control Directors/Coordinators, Pharmacists, Nurses, Physicians, Microbiology, Environmental Cleaning, Quality Improvement)	28	10	38
Hospital Executives (e.g., Chief nursing or medical officers)	4	0	4
Frontline health care providers (nurses, physicians, pharmacy staff, program coordinator)	5*	5	10
Total	**37**	**15**	**52**
Response Rate	**74%**	**38%**	**58%**

*Note: Two front line healthcare provider staff respondents completed telephone interviews instead of surveys.
±Note: Follow-up interview and survey participants in some cases were the same and in some cases were different than those who participated in Round 1 interviews and surveys.
Table created by the authors

Appendix Table 2: Regression Model Demonstrating the Impact of Statewide Prevention and Reduction of C. difficile (SPARC) Collaborative

	Incidence rate ratios (IRR)	95% Confidence Interval	P value
Evaluation group			
Control	1		
SPARC intervention	1.64	(1.14 − 2.37)	0.008
Intervention phase			
Pre-SPARC Quarter 1	1		
Pre-SPARC Quarter 2	1.06	(0.85 − 1.31)	0.619
Pre-SPARC Quarter 3	0.89	(0.71 − 1.11)	0.310
Pre-SPARC Quarter 4	0.73	(0.58 − 0.91)	0.007
Post-SPARC Quarter 1	0.79	(0.63 − 0.99)	0.039
Post-SPARC Quarter 2	0.71	(0.57 − 0.90)	0.004
Post-SPARC Quarter 3	0.80	(0.64 − 1.00)	0.054
Post-SPARC Quarter 4	0.77	(0.61 − 0.96)	0.024
Post-SPARC Quarter 5	0.73	(0.58 − 0.92)	0.009
Post-SPARC Quarter 6	0.73	(0.57 − 0.93)	0.011
Interactions of evaluation groups and intervention phases			
Pre-SPARC Quarter 1	1		
Pre-SPARC Quarter 2	0.90	(0.64 − 1.27)	0.560
Pre-SPARC Quarter 3	0.96	(0.67 − 1.37)	0.814
Pre-SPARC Quarter 4	1.02	(0.71 − 1.46)	0.930
Post-SPARC Quarter 1	0.73	(0.50 − 1.06)	0.098
Post-SPARC Quarter 2	0.56	(0.38 − 0.84)	0.005
Post-SPARC Quarter 3	0.46	(0.31 − 0.69)	<0.001
Post-SPARC Quarter 4	0.51	(0.34 − 0.77)	0.001
Post-SPARC Quarter 5	0.50	(0.33 − 0.75)	0.001
Post-SPARC Quarter 6	0.55	(0.35 − 0.88)	0.012
Predicted *C. difficile* count	1.02	(1.01 − 1.03)	<0.001

*Difference-in-difference analytic approach using random intercept negative binomial mixed model that regresses *C. difficile* count on a dichotomous variable indicating evaluation group (SPARC vs. control); dummy variables for the time periods (i.e., 4 pre-SPARC quarters and 6 post-SPARC quarters); and interactions of the evaluation group and the time period dummy variables, and National Healthcare Safety Network-predicted *C. difficile* count with an offset of patient days. The interactions terms represented the impact of the SPARC program.
Table created by the authors

Appendix Table 3: Interaction of Participating Hospitals with the SPARC Collaborative

Hospital	Implementation Planning					Technical Assistance Interactions				
	Gap Assessment	Site Visit	Feedback Report	Site Visit Feedback Report Call	Intervention Implementation Plan Complete	1st Check-in	Provided Updated Plan (Date of Last)	Attended Webinars*	Attended In-Person Meeting*	Attended Training*
A	X	6/27/2018	8/21/2018					X		X
B	X	9/19/2018	X	X	X	X	10/07/19	X		
C	X	10/25/2018	X	X	X	X	7/24/19	X	X	X
D	X	11/5/2018	X	X	X	X	10/29/19	X		
E	X	11/16/2018	X	X	X	X	10/29/19	X		X
F	X	12/3/2018	X	X	X	X	2/12/20	X		X
G	X	1/11/2019	X	X	X	X	6/10/20	X	X	X
H	X	1/23/2019	X	X	X	X	11/21/19	X	X	X
I	X	3/14/2019	X	X	X	X	11/14/19	X		X
J	X	3/25/2019	X	10/24/2019						X
K	X	4/18/2019	X	X	X	X	12/30/19		X	
L	X	8/21/2019	X	10/9/2019				X	X	

*Attendance by participating hospitals at the various Technical Assistance events is likely underrepresented, as some events only collected participant name and not affiliated hospitals and, in some cases, participants did not report their hospital even when it was requested.
Table created by the authors